Investment Analysts’ Recent Ratings Updates for SAB Biotherapeutics (SABS)

Several brokerages have updated their recommendations and price targets on shares of SAB Biotherapeutics (NASDAQ: SABS) in the last few weeks:

• 5/22/2026 – SAB Biotherapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $11.00 price target on the stock.
• 5/20/2026 – SAB Biotherapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $11.00 price target on the stock.
• 5/20/2026 – SAB Biotherapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $11.00 price target on the stock.
• 5/12/2026 – SAB Biotherapeutics had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a “buy” rating on the stock.
• 5/11/2026 – SAB Biotherapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 5/11/2026 – SAB Biotherapeutics had its “buy” rating reaffirmed by Rodman & Renshaw. They now have a $13.00 price target on the stock.
• 4/10/2026 – SAB Biotherapeutics had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 4/2/2026 – SAB Biotherapeutics is now covered by Rodman & Renshaw. They set a “buy” rating and a $13.00 price target on the stock.

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.